Arcutis Biotherapeutics Inc (ARQT) News

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Arcutis Canada annonce l'acceptation aux fins d'examen par Santé Canada de la présentation de la crème de roflumilast à 0,15 % pour le traitement de la dermatite atopique chez les adultes et les enfants âgés de 6 ans et plus

Arcutis Canada annonce l'acceptation aux fins d'examen par Santé Canada de la présentation...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update

First quarter net product revenues for ZORYVE® franchise of $21.6M, with $15M for ZORYVE (roflumilast) cream...

US Futures Remain Steady Amid Wall Street Caution Ahead of April PPI Report

U.S. index futures are almost unchanged in pre-market trading this Tuesday, reflecting Wall Street’s...

Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology

Eight of nine experts expressed feeling “extremely confident” about prescribing ZORYVE foam to patients of...

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a...

Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

WESTLAKE VILLAGE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a...

Arcutis Appoints David Topper as Chief Financial Officer

WESTLAKE VILLAGE, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a...

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a...

Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream

NESS ZIONA, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a...

Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference

WESTLAKE VILLAGE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a...